Please wait

Exhibit 107.1

Calculation of Filing Fee Table

Form S-3

(Form Type)

CytomX Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and

Carry Forward Securities

 

                         
    

Security

Type

 

Security Class

Title

  Fee
Calculation 
or Carry
Forward
Rule
  Amount
Registered
  Proposed
Maximum 
Offering
Price Per
Unit
  Maximum
Aggregate
Offering
Price
  Fee
Rate
  Amount of
Registration
Fee
 

Carry
Forward

Form
Type

 

Carry

Forward

File

Number

  Carry
Forward
Initial
Effective
date
  Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
                         
Fees to Be Paid                          
                         
    Equity   Common Stock,  par value $0.00001 per share (1)                      
                         
    Equity   Preferred Stock,  par value $0.00001 per share (1)                      
                         
    Debt   Debt Securities                      
                         
    Other   Warrants                      
                         
    Other   Units                      
                         
    Unallocated  (Universal) Shelf   (2)   Rule 457(o)   $250,000,000   N/A   $4,993,258.39(3)(4)   $0.00014760   $737.01(4)          
                         
Fees Previously  Paid                          
 
Carry Forward Securities
                         
Carry Forward Securities   Unallocated (Universal) Shelf   (2)   Rule 415(a)(6)    $245,006,741.61(4)       $245,006,741.61(4)        Form S-3  

333-

258510 

  8/18/2021   $26,730.23
                   
   

Total Offering Amounts 

    $250,000,000     $737.01          
                   
    Total Fees Previously Paid                   
                   
    Total Fee Offsets                   
                   
    Net Fee Due                $737.01                

 

(1)

Includes rights to acquire common stock or preferred stock of CytomX Therapeutics, Inc. (the “Registrant”) under any shareholder rights plan then in effect, if applicable under the terms of any such plan.

(2)

An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.

(3)

Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities, depositary shares or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $250,000,000.

(4)

The Registrant previously paid registration fees in the aggregate of $27,275.00 with respect to its Registration Statement on Form S-3 (File No. 333-258510) (the “Prior Registration Statement”). Pursuant to Rule 415(a)(6) (“Rule 415(a)(6)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the securities registered pursuant to this Registration Statement on Form S-3 (this “Registration Statement”) include $245,006,741.61 of securities previously registered on the Prior Registration Statement which remain unsold (the “Unsold Securities”). Pursuant to Rule 415(a)(6), the registration fee of $26,730.23 associated with the offering of the Unsold Securities (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement) is hereby carried forward to be applied to the Unsold Securities registered hereunder, and no additional filing fee is due with respect to the Unsold Securities in connection with the filing of this Registration Statement. The registrant is also registering new securities on this Registration Statement with an aggregate maximum offering price of $4,993,258.39 (the “New Securities”), which aggregate offering price is not specified as to each class of securities in reliance upon Rule 457(o) promulgated under the Securities Act. A filing fee of $737.01 with respect to the New Securities is being paid in connection with the filing of this Registration Statement. To the extent that, after the filing date hereof and prior to the effectiveness of this Registration Statement, the Registrant sells any Unsold Securities pursuant to the Prior Registration Statement, the Registrant will identify in a pre-effective amendment to this Registration Statement the updated number of Unsold Securities from the Prior Registration Statement to be included in this Registration Statement pursuant to Rule 415(a)(6) and the updated amount of additional new securities to be registered on this Registration Statement. Pursuant to Rule 415(a)(6), the offering of the Unsold Securities under the Prior Registration Statement will be deemed terminated as of the date of effectiveness of this Registration Statement.